{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:40:40Z","timestamp":1788489640627,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"am","delay-in-days":425,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006537","name":"Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DK081646"],"award-info":[{"award-number":["R01-DK081646"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DK101791"],"award-info":[{"award-number":["R01-DK101791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1053\/j.ackd.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T19:57:33Z","timestamp":1567195053000},"page":"253-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience"],"prefix":"10.1053","volume":"26","author":[{"given":"Neil S.","family":"Sanghani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker H.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.ackd.2019.04.004_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"20","key":"10.1053\/j.ackd.2019.04.004_bib2","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2215\/CJN.02730608","article-title":"Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis","volume":"4","author":"Parfrey","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib5","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2215\/CJN.06450710","article-title":"Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial","volume":"6","author":"Lewis","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2019.04.004_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ackd.2019.04.004_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"issue":"21","key":"10.1053\/j.ackd.2019.04.004_bib9","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ackd.2008.12.007","article-title":"What is so bad about a hemoglobin level of 12 to 13 g\/dL for chronic kidney disease patients anyway?","volume":"16","author":"Besarab","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"10.1053\/j.ackd.2019.04.004_bib11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2019.04.004_bib12","first-page":"S110","article-title":"HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism","volume":"21","author":"Haase","year":"2017","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1152\/jappl.1972.32.1.54","article-title":"Plasma erythropoietin in men and mice during acclimatization to different altitudes","volume":"32","author":"Abbrecht","year":"1972","journal-title":"J Appl Physiol"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2011-03-341776","article-title":"Regulation of hepcidin expression at high altitude","volume":"119","author":"Talbot","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"10.1053\/j.ackd.2019.04.004_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev-physiol-021909-135922","article-title":"Mammalian Per-Arnt-Sim proteins in environmental adaptation","volume":"72","author":"McIntosh","year":"2010","journal-title":"Annu Rev Physiol"},{"issue":"7724","key":"10.1053\/j.ackd.2019.04.004_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(71)80127-7","article-title":"Use of cobaltous chloride in anaemia of maintenance hemodialysis patients","volume":"2","author":"Edwards","year":"1971","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/dta.1528","article-title":"Intolerability of cobalt salt as erythropoietic agent","volume":"6","author":"Ebert","year":"2014","journal-title":"Drug Test Anal"},{"issue":"23","key":"10.1053\/j.ackd.2019.04.004_bib19","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1021\/jm400386j","article-title":"Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses","volume":"56","author":"Rabinowitz","year":"2013","journal-title":"J Med Chem"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nchembio0308-152","article-title":"Expanding chemical biology of 2-oxoglutarate oxygenases","volume":"4","author":"Loenarz","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"11","key":"10.1053\/j.ackd.2019.04.004_bib21","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1039\/C7SC02103H","article-title":"Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials","volume":"8","author":"Yeh","year":"2017","journal-title":"Chem Sci"},{"key":"10.1053\/j.ackd.2019.04.004_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by\u00a0hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1357-2725(03)00211-5","article-title":"The mammalian basic helix-loop-helix\/PAS family of transcriptional regulators","volume":"36","author":"Kewley","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"issue":"306","key":"10.1053\/j.ackd.2019.04.004_bib24","doi-asserted-by":"crossref","first-page":"re12","DOI":"10.1126\/stke.3062005re12","article-title":"Integration of oxygen signaling at the consensus HRE","volume":"2005","author":"Wenger","year":"2005","journal-title":"Sci STKE"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib25","doi-asserted-by":"crossref","first-page":"C260","DOI":"10.1152\/ajpcell.00315.2015","article-title":"Hypoxia-inducible factor 3 biology: complexities and emerging themes","volume":"310","author":"Duan","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in\u00a0vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1053\/j.ackd.2019.04.004_bib27","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib28","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI83551","article-title":"Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin","volume":"126","author":"Kobayashi","year":"2016","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1053\/j.ackd.2019.04.004_bib29","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","article-title":"High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq","volume":"117","author":"Schodel","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney\u00a0disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am J Nephrol"},{"issue":"Jan 15","key":"10.1053\/j.ackd.2019.04.004_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2018.11.023","article-title":"Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation [published online November 17, 2018]","volume":"843","author":"Jain","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"16","key":"10.1053\/j.ackd.2019.04.004_bib32","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1111\/bph.13188","article-title":"Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats","volume":"172","author":"Barrett","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib35","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2019.04.004_bib37","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/bcp.13584","article-title":"First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia","volume":"84","author":"Bottcher","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13318-018-0480-z","article-title":"Effect of multiple doses of omeprazole on the pharmacokinetics, safety, and tolerability of roxadustat in healthy subjects","volume":"43","author":"Groenendaal-van de Meent","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"10.1053\/j.ackd.2019.04.004_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-016-0422-y","article-title":"Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor\u00a0prolyl hydroxylase inhibitor","volume":"36","author":"Groenendaal-van de Meent","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2016.02.010","article-title":"The hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) and warfarin in healthy volunteers: a pharmacokinetic and pharmacodynamic drug-drug interaction study","volume":"38","author":"Groenendaal-van de Meent","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/jcpt.12729","article-title":"Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects","volume":"43","author":"Shibata","year":"2018","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib42","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib43","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2019.04.004_bib44","first-page":"747A","article-title":"Dose exposure relationship of AKB-6548 is independent of the level of renal function","volume":"26","author":"Buch","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2019.04.004_bib46","first-page":"435A","article-title":"AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia","volume":"22","author":"Hartman","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for\u00a0anemia: a 24-week, open-label, randomized controlled trial\u00a0in\u00a0participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib52","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2019.04.004_bib53","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/ndt\/gfy055","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents","volume":"34","author":"Haase","year":"2019","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib55","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib56","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2019.04.004_bib57","first-page":"B5","article-title":"A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis","volume":"29","author":"Chen","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2019.04.004_bib58","first-page":"304A","article-title":"Efficacy and dose requirements of vadadustat are independent of systemic inflammation and prior erythropoiesis-stimulating agent (ESA) dose in patients with non-dialysis dependent chronic kidney disease (NDD-CKD)","volume":"27","author":"Haase","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib59","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.117.242503","article-title":"Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia","volume":"363","author":"Ariazi","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/cpdd.83","article-title":"Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863","volume":"3","author":"Johnson","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib61","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/cpdd.342","article-title":"A randomized, placebo- and positive-controlled, single-dose, crossover thorough QT\/QTc study assessing the effect of daprodustat on cardiac repolarization in healthy subjects","volume":"6","author":"Caltabiano","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib62","doi-asserted-by":"crossref","first-page":"e00327","DOI":"10.1002\/prp2.327","article-title":"The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects","volume":"6","author":"Caltabiano","year":"2018","journal-title":"Pharmacol Res Perspect"},{"issue":"8","key":"10.1053\/j.ackd.2019.04.004_bib63","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejca.2005.01.021","article-title":"Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa","volume":"41","author":"Glaspy","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib64","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/CCM.0b013e31819cec94","article-title":"Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss","volume":"37","author":"Arroliga","year":"2009","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib65","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"10.1053\/j.ackd.2019.04.004_bib66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib67","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib68","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib69","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOH.0000000000000132","article-title":"New insights into iron regulation and erythropoiesis","volume":"22","author":"Kim","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"issue":"12","key":"10.1053\/j.ackd.2019.04.004_bib71","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib72","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.ackd.2019.04.004_bib73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib74","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00174.2010","article-title":"Hypoxic regulation of erythropoiesis and iron metabolism","volume":"299","author":"Haase","year":"2010","journal-title":"Am J Physiol Ren Physiol"},{"issue":"22","key":"10.1053\/j.ackd.2019.04.004_bib75","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib76","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/BJ20111377","article-title":"Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia","volume":"441","author":"Shen","year":"2012","journal-title":"Biochem J"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib77","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","article-title":"Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD","volume":"73","author":"Bajaj","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ackd.2019.04.004_bib78","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib79","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI84433","article-title":"Hypoxia-dependent regulation of inflammatory pathways in immune cells","volume":"126","author":"Taylor","year":"2016","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1053\/j.ackd.2019.04.004_bib80","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrd4422","article-title":"Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases","volume":"13","author":"Eltzschig","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib81","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/JIM.0000000000000218","article-title":"Targeting hypoxia in inflammatory bowel disease","volume":"64","author":"Colgan","year":"2016","journal-title":"J Investig Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib82","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib83","doi-asserted-by":"crossref","first-page":"F821","DOI":"10.1152\/ajprenal.00224.2015","article-title":"Molecular mechanisms of ischemic preconditioning in the kidney","volume":"309","author":"Kapitsinou","year":"2015","journal-title":"Am J Physiol Ren Physiol"},{"issue":"9889","key":"10.1053\/j.ackd.2019.04.004_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"suppl 3","key":"10.1053\/j.ackd.2019.04.004_bib85","doi-asserted-by":"crossref","first-page":"iii28","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino","year":"2018","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib86","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jama.2009.84","article-title":"Altitude and all-cause mortality in incident dialysis patients","volume":"301","author":"Winkelmayer","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib87","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/ndt\/gfr681","article-title":"Altitude and the risk of cardiovascular events in incident US dialysis patients","volume":"27","author":"Winkelmayer","year":"2012","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib88","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/ng1019","article-title":"Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia","volume":"32","author":"Ang","year":"2002","journal-title":"Nat Genet"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib89","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2003-07-2535","article-title":"Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors","volume":"103","author":"Gordeuk","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ackd.2019.04.004_bib90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2006-939441","article-title":"Vascular complications in Chuvash polycythemia","volume":"32","author":"Gordeuk","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.ackd.2019.04.004_bib91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-pathol-011110-130321","article-title":"The HIF pathway and erythrocytosis","volume":"6","author":"Lee","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib92","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1172\/JCI120855","article-title":"Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers","volume":"129","author":"Chappell","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2012.06.001","article-title":"The VHL\/HIF axis in clear cell renal carcinoma","volume":"23","author":"Shen","year":"2012","journal-title":"Semin Cancer Biol"},{"issue":"7456","key":"10.1053\/j.ackd.2019.04.004_bib94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1053\/j.ackd.2019.04.004_bib95","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7627","key":"10.1053\/j.ackd.2019.04.004_bib96","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"7627","key":"10.1053\/j.ackd.2019.04.004_bib97","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"key":"10.1053\/j.ackd.2019.04.004_bib98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.critrevonc.2017.01.013","article-title":"Targeting HIF-2 alpha in clear cell renal cell carcinoma: a promising therapeutic strategy","volume":"111","author":"Martinez-Saez","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib99","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2019.04.004_bib100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/ERC-16-0231","article-title":"Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome","volume":"23","author":"Darr","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1053\/j.ackd.2019.04.004_bib101","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"25","key":"10.1053\/j.ackd.2019.04.004_bib102","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2011.044644","article-title":"Distinct deregulation of the\u00a0hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia","volume":"97","author":"Ladroue","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.ackd.2019.04.004_bib104","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/s41467-018-05554-1","article-title":"HIF-2alpha-pVHL complex reveals broad genotype-phenotype correlations in HIF-2alpha-driven disease","volume":"9","author":"Tarade","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.ackd.2019.04.004_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"issue":"6","key":"10.1053\/j.ackd.2019.04.004_bib106","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1091581817737232","article-title":"Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats","volume":"36","author":"Beck","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1053\/j.ackd.2019.04.004_bib107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1749-6632.2009.05030.x","article-title":"Pathophysiological consequences of HIF activation: HIF as a modulator of fibrosis","volume":"1177","author":"Haase","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1053\/j.ackd.2019.04.004_bib108","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"issue":"16","key":"10.1053\/j.ackd.2019.04.004_bib109","first-page":"5071","article-title":"Effects of HIF-1alpha on diabetic retinopathy angiogenesis and VEGF expression","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/j.ajkd.2012.07.029","article-title":"Pulmonary hypertension in CKD","volume":"61","author":"Bolignano","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ackd.2019.04.004_bib111","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00439-011-1109-3","article-title":"Genetic determinants of Tibetan high-altitude adaptation","volume":"131","author":"Simonson","year":"2012","journal-title":"Hum Genet"},{"key":"10.1053\/j.ackd.2019.04.004_bib112","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1038\/ncomms7863","article-title":"Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension","volume":"6","author":"Newman","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1053\/j.ackd.2019.04.004_bib113","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/MCB.01055-15","article-title":"The endothelial prolyl-4-hydroxylase domain 2\/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice","volume":"36","author":"Kapitsinou","year":"2016","journal-title":"Mol Cell Biol"},{"issue":"31","key":"10.1053\/j.ackd.2019.04.004_bib114","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1073\/pnas.1602978113","article-title":"HIF2alpha-arginase axis is essential for the development of pulmonary hypertension","volume":"113","author":"Cowburn","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2019.04.004_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol"},{"issue":"8","key":"10.1053\/j.ackd.2019.04.004_bib116","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1681\/ASN.2016010030","article-title":"Hepatitis C virus infection in chronic kidney disease","volume":"27","author":"Ladino","year":"2016","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300928?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519300928?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:32:06Z","timestamp":1778617926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519300928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1548559519300928"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.04.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736573711.793577773","asserted-by":"object"}]},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}